Company Overview of Icogenex Corporation
Icogenex Corporation, a biotechnology company, identifies and develops therapeutic compounds for the treatment of human diseases. The company provides research and development in the fields of Alzheimer's disease and inflammation, as well as produces therapeutic proteins from bacteria, yeast, or mammalian cells. Its products are used to treat inflammatory diseases, Alzheimer's disease, and diseases involving inappropriate proteolytic processing. Icogenex was formerly known as Icogen Corporation and changed its name in February 2004. The company was founded in 1995 and is headquartered in Seattle, Washington.
454 North 34th Street
Seattle, WA 98103
Founded in 1995
Key Executives for Icogenex Corporation
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Icogenex Corporation, please visit www.icogenex.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.